Bressler NM, et al. - In this post hoc analysis involving 652 candidates,, researchers explored connections between changes in visual acuity (VA) and changes in optical coherence tomography (OCT) central subfield thickness (CST) across 3 anti-vascular endothelial growth factor (anti-VEGF) agents (aflibercept, bevacizumab, or ranibizumab) utilized in a randomized clinical trial for diabetic macular edema. According to findings, changes in CST appear to represent only a small proportion of the total variation in VA changes. These results do not support the use of modifications in OCT CST as a surrogate for modifications in VA in phase 3 clinical trials assessing anti-VEGF for diabetic macular edema or as a guide to educate the doctor or patient after anti-VEGF treatment about modifications in VA.